Schonfeld Strategic Advisors LLC Akero Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$13.8 Billion
Q3 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 278,323 shares of AKRO stock, worth $8.91 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

278,323

Previous 441,794 37.0%

Holding current value

$8.91 Million

Previous $10.4 Million 22.95%

% of portfolio

0.06%

Previous 0.07%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $3.51 Million - $4.8 Million	-163,471 Reduced 37.0%	278,323 $7.99 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $4.65 Million - $6.25 Million	-253,929 Reduced 36.5%	441,794 $10.4 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $9.97 Million - $17.5 Million	561,371 Added 417.84%	695,723 $17.6 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $883,725 - $3.91 Million	-77,656 Reduced 36.63%	134,352 $3.14 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $1.52 Million - $1.92 Million	36,808 Added 21.01%	212,008 $10.7 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $4.26 Million - $6.57 Million	115,522 Added 193.58%	175,200 $8.18 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $1.43 Million - $1.93 Million	-38,478 Reduced 39.2%	59,678 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $2.98 Million - $4.89 Million	89,256 Added 1002.88%	98,156 $5.38 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $152,250 - $510,749	-15,000 Reduced 62.76%	8,900 $303,000
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $116,000 - $217,645	14,500 Added 154.26%	23,900 $225,000
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $233,214 - $304,090	9,400 New	9,400 $234,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Akero Therapeutics, Inc. Transaction History